Business News • PR NewsWire • European Hematology Association: Humoral Response to the Pfizer/BioNTech BNT162b2 Vaccine Is Impaired in Patients Receiving CAR-T or High-Intensity Immunosuppressive Therapy

European Hematology Association: Humoral Response to the Pfizer/BioNTech BNT162b2 Vaccine Is Impaired in Patients Receiving CAR-T or High-Intensity Immunosuppressive Therapy

European Hematology Association: Humoral Response to the Pfizer/BioNTech BNT162b2 Vaccine Is Impaired in Patients Receiving CAR-T or High-Intensity Immunosuppressive Therapy

THE HAGUE, Netherlands, June 12, 2021 /PRNewswire/ -- The Pfizer/BioNTech BNT162b2 vaccine has been approved for the prevention of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and is recommended for immunosuppressed patients. However, its efficacy and safety in...

View More : https://www.prnewswire.com:443/news-releases/european-hematology-association-humoral-response-to-the-pfizerbiontech-bnt1...

Releted News by prnewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates USCR, ONEM, QTS, MCF; Shareholders are Encouraged to Contact the Firm

Risen Energy Unveils NewT@N at SNEC 2021, the Industry's First Mass-Produced 700W High-Efficiency Power Module

Long-lasting Chlorine Dioxide (ClO2) Aqueous Solution Presented by Taiko Pharmaceutical and Kitasato University Inactivates over 99.99% of SARS-CoV-2 (COVID-19 Virus)

European Hematology Association: Humoral Response to the Pfizer/BioNTech BNT162b2 Vaccine Is Impaired in Patients Receiving CAR-T or High-Intensity Immunosuppressive Therapy

European Hematology Association - Pegcetacoplan Maintains a Durable Response in Patients with Paroxysmal Nocturnal Hemoglobinuria Through Week 48

European Hematology Association- First-Line Ibrutinib + Venetoclax Is Superior to Chlorambucil + Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocyte Lymphoma

USD 0.66 Billion growth expected in Health Economics Outcomes Research Services Market| SpendEdge